Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pfizer
Pharma
Experts paint tough path ahead of Alnylam's key ATTR-CM readout
Pfizer's tafamidis is expected to maintain the lion’s share of the ATTR-CM market even if Alnylam’s HELIOS-B trial were to be positive, two KOLs said.
Angus Liu
Apr 22, 2024 10:55am
AbbVie tops, J&J drops as physicians rank immunology players
Apr 19, 2024 7:30am
Pfizer focuses on long COVID in latest 'Dear Scientist' video
Apr 17, 2024 1:10pm
Judge pauses Moderna's infringement case against rival Pfizer
Apr 15, 2024 4:47pm
Top 20 pharma companies by 2023 revenue
Apr 15, 2024 3:00am
Lady Gaga's post about Pfizer Nurtec ODT ad earns EU ire
Apr 12, 2024 12:07pm